# Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

> **NCT03137407** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 59 (actual)

## Conditions studied

- Plantar Fasciitis

## Interventions

- **BIOLOGICAL:** Botulinum Toxins, Type A
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03137407
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-02-20
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03137407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03137407, "Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03137407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*